Patents by Inventor Petr Dzubak
Petr Dzubak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11766404Abstract: A particulate form of dithiocarbamate-metal complex and at least one blood protein. The particulate form is obtained by a process having a sequential or simultaneous addition of individual components, resulting in their self-assembling. The aqueous dispersion of the particulate form is suitable for parenteral, oral and topical administration and for therapy and visualization of cancer.Type: GrantFiled: September 26, 2018Date of Patent: September 26, 2023Assignee: PALACKY UNIVERSITY OLOMOUCInventors: Zdenek Skrott, Martin Mistrik, Marian Hajduch, Petr Dzubak, Jiri Bartek, Radek Zboril
-
Patent number: 11299510Abstract: Substituted pyridopyrrolopyrimidine ribonucleosides of general formula I, wherein R is as described in the independent claim, preferably R is selected from the group comprising thiophen-3-yl, furan-2-yl, furan-3-yl, benzofuran-2-yl, methylsulfanyl, methoxy, amino, dimethylamino, methyl; and pharmaceutically acceptable salt thereof, their optical isomers and mixtures of such optical isomers. Compounds according to the invention show strong cytostatic and cytotoxic effects on cell lines of tumor origin in a wide variety of diseases including tumors of different histogenetic origin.Type: GrantFiled: March 4, 2019Date of Patent: April 12, 2022Assignees: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., UNIVERZITA PALACKEHO V OLOMOUCIInventors: Lucia Veselovska, Michal Hocek, Marian Hajduch, Petr Dzubak
-
Publication number: 20220000914Abstract: A complex particle form of dithiocarbamate-metal compound and at least one ligand, that is a polymer or a detergent is disclosed. The complex particle form is obtained by a process having a sequential or simultaneous addition of individual components, resulting in their self-assembling. The dry form or aqueous dispersion of the complex particle form is suitable for medicinal per-oral, topical and parenteral administration and for therapy and imaging of cancer.Type: ApplicationFiled: October 8, 2019Publication date: January 6, 2022Applicant: PALACKY UNIVERSITY OLOMOUCInventors: Martin MISTRIK, Jiri BARTEK, Zdenek SKROTT, Petr DZUBAK, Marian HAJDUCH
-
Publication number: 20210241851Abstract: A method for determination of identity of at least one entity from a mass spectrum of at least one entity and from additional data from chemical, physical, biochemical or biological analysis of at least one entity for each entity having the steps of a) collecting analytical data from mass spectrum of the entity, b) obtaining a plurality and prevalences of candidate identities, c) calculation of its score, and d) determining the identity of an entity as the candidate identity with the score closest to the score that would correspond to the true identity of the entity. The entity may be any chemical or biological entity, in particular a peptide, a protein, a lipid, a nucleic acid, a metabolite or a small molecule.Type: ApplicationFiled: July 19, 2019Publication date: August 5, 2021Applicant: UNlVERZlTA PALACKEHO V OLOMOUClInventors: Miroslav HRUSKA, Marian HAJDUCH, Petr DZUBAK
-
Publication number: 20210002321Abstract: Substituted pyridopyrrolopyrimidine ribonucleosides of general formula I, wherein R is as described in the independent claim, preferably R is selected from the group comprising thiophen-3-yl, furan-2-yl, furan-3-yl, benzofuran-2-yl, methylsulfanyl, methoxy, amino, dimethylamino, methyl; and pharmaceutically acceptable salt thereof, their optical isomers and mixtures of such optical isomers. Compounds according to the invention show strong cytostatic and cytotoxic effects on cell lines of tumor origin in a wide variety of diseases including tumors of different histogenetic origin.Type: ApplicationFiled: March 4, 2019Publication date: January 7, 2021Applicants: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., UNIVERZITA PALACKEHO V OLOMOUCIInventors: Lucia VESELOVSKA, Michal HOCEK, Marian HAJDUCH, Petr DZUBAK
-
Publication number: 20200276124Abstract: A particulate form of dithiocarbamate-metal complex and at least one blood protein. The particulate form is obtained by a process having a sequential or simultaneous addition of individual components, resulting in their self-assembling. The aqueous dispersion of the particulate form is suitable for parenteral, oral and topical administration and for therapy and visualization of cancer.Type: ApplicationFiled: September 26, 2018Publication date: September 3, 2020Applicant: PALACKY UNIVERSITY OLOMOUCInventors: Zdenek SKROTT, Martin MISTRIK, Marian HAJDUCH, Petr DZUBAK, Jiri BARTEK, Radek ZBORIL
-
Patent number: 10759826Abstract: 15?-substituted derivatives of estrone of general formula I wherein R1, R2, R3, R4, R5 are independently selected from the group consisting of: C1-C4 alkyl, C1-C4 alkoxy, C1-C4 halogenalkyl, halogen, COOR6 wherein R6 is C1-C4 alkyl; H, OH; optionally, R3, R4 and R5 are each formed by a hydrogen atom, while R1 and R2 together form an aryl group, preferably naphthyl, in which the aromatic ring in position C-15 can be mono-, di-, tri-, tetra- and penta-substituted with substituents R1-R5. Compounds of the invention may be used for diagnosis and possibly also for the treatment of estrogen-dependent diseases.Type: GrantFiled: June 7, 2017Date of Patent: September 1, 2020Assignees: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., USTAV MOLEKULARNI GENETIKY AKADEMIE VED CR, V.V.I., UNIVERZITA PALACKEHO V OLOMOUCI, HELMHOLTZ ZENTRUM MUNCHENInventors: Martin Kotora, Eva Prchalova, Jerzy Adamski, Gabriele Moeller, Ondrej Stepanek, Petr Bartunek, David Sedlak, Marian Hajduch, Petr Dzubak
-
Patent number: 10730905Abstract: Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides of general formula I, where R is selected from the group comprising furan-2-yl, furan-3-yl, benzofuran-2-yl, methylsulfanyl, methoxy, amino, dimethylamino, methyl or chloro, and pharmaceutically acceptable salt thereof, their optical isomers and mixtures of such optical isomers.Type: GrantFiled: July 31, 2017Date of Patent: August 4, 2020Assignees: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., UNIVERZITA PALACKEHO V OLOMOUCIInventors: Michal Hocek, Anna Tokarenko, Sabina Smolen, Marian Hajduch, Petr Dzubak
-
Publication number: 20190330258Abstract: 15?-substituted derivatives of estrone of general formula I wherein R1, R2, R3, R4, R5 are independently selected from the group consisting of: C1-C4 alkyl, C1-C4 alkoxy, C1-C4 halogenalkyl, halogen, COOR6 wherein R6 is C1-C4 alkyl; H, OH; optionally, R3, R4 and R5 are each formed by a hydrogen atom, while R1 and R2 together form an aryl group, preferably naphthyl, in which the aromatic ring in position C-15 can be mono-, di-, tri-, tetra- and penta-substituted with substituents R1-R5. Compounds of the invention may be used for diagnosis and possibly also for the treatment of estrogen-dependent diseases.Type: ApplicationFiled: June 7, 2017Publication date: October 31, 2019Applicants: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., USTAV MOLEKULARNI GENETIKY AKADEMIE VED CR, V.V.I., UNIVERZITA PALACKEHO V OLOMOUCI, HELMHOLTZ ZENTRUM MUNCHENInventors: Martin KOTORA, Eva PRCHALOVA, Jerzy ADAMSKI, Gabriele MOELLER, Ondrej STEPANEK, Petr BARTUNEK, David SEDLAK, Marian HAJDUCH, Petr DZUBAK
-
Patent number: 10414788Abstract: A group of substituted thienopyrrolopyrimidine ribonucleosides of general formula I, in which R shows strong cytostatic and cytotoxic activities preferably against cancer cell lines of broad spectrum of diseases including tumors of various histogenetic origin.Type: GrantFiled: June 29, 2016Date of Patent: September 17, 2019Assignees: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., UNIVERZITA PALACKEHO V OLOMOUCIInventors: Michal Hocek, Michal Tichy, Marian Hajduch, Petr Dzubak
-
Publication number: 20190144487Abstract: A group of substituted thienopyrrolopyrimidine ribonucleosides of general formula I, in which R shows strong cytostatic and cytotoxic activities preferably against cancer cell lines of broad spectrum of diseases including tumors of various histogenetic origin.Type: ApplicationFiled: June 29, 2016Publication date: May 16, 2019Applicants: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., UNIVERZITA PALACKEHO V OLOMOUCIInventors: MICHAL HOCEK, Michal TICHY, Marian HAJDUCH, Petr DZUBAK
-
Publication number: 20190144486Abstract: Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides of general formula I, where R is selected from the group comprising furan-2-yl, furan-3-yl, benzofuran-2-yl, methylsulfanyl, methoxy, amino, dimethylamino, methyl or chloro, and pharmaceutically acceptable salt thereof, their optical isomers and mixtures of such optical isomers.Type: ApplicationFiled: July 31, 2017Publication date: May 16, 2019Applicants: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., UNIVERZITA PALACKEHO V OLOMOUCIInventors: Michal HOCEK, Anna TOKARENKO, Sabina SMOLEN, Marian HAJDUCH, Petr DZUBAK
-
Publication number: 20180251847Abstract: Method for predicting sensitivity of a patient suffering from cancer to DNA methylation inhibitor therapy uses in vitro in cancer cells taken from the patient. Cells are compared with parent type cells for expression of bromodomain containing genes, of other listed genes, and/or of bromodomain containing proteins. Mutations involving the amino acid sequence of bromodomain containing genes and/or mutations involving non-synonymous change in amino acid sequence of other genes may be examined. The half maximal inhibitory concentration (IC50) of inhibitors of DNA methyltransferase, histone acetyltransferase, histone methyltransferase, histone deacetylases, and/or histone demethylases are determined. Increase in (IC50) signifies cross-resistance. The half maximal inhibitory concentration (IC50) of a selective BET bromodomain inhibitor is also determined, wherein decrease in the (IC50) signifies sensitivity.Type: ApplicationFiled: March 27, 2015Publication date: September 6, 2018Applicant: PALACKY UNIVERSITY, OLOMOUCInventors: Khushboo AGRAWAL, Petr DZUBAK, Ivo FRYDRYCH, Marian HAJDUCH
-
Patent number: 9586986Abstract: Compounds of Formula I and a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a mixture of optical isomers thereof, as well as compositions which include such compounds and therapeutic methods that utilize such compounds and/or compositions.Type: GrantFiled: December 5, 2014Date of Patent: March 7, 2017Assignees: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I., PALACKY UNIVERSITY IN OLOMOUCInventors: Michal Hocek, Petr Naus, Olga Caletkova, Marian Hajduch, Petr Dzubak
-
Publication number: 20160159844Abstract: Compounds of Formula I and a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a mixture of optical isomers thereof, as well as compositions which include such compounds and therapeutic methods that utilize such compounds and/or compositions.Type: ApplicationFiled: December 5, 2014Publication date: June 9, 2016Applicants: Institute of Organic Chemistry and Biochemistry ASCR, v.v.i., Palacky University in OlomoucInventors: Michal HOCEK, Petr NAUS, Olga CALETKOVA, Marian HAJDUCH, Petr DZUBAK
-
Patent number: 9290529Abstract: Derivatives of boron cluster compounds of general formula I and their pharmaceutically acceptable salts and solvates, and their specific inhibition effect on the enzyme carbonic anhydrase IX, a protein overexpressed in cancer tissues. Methods of synthesis and the use of the novel derivatives. These inhibitors of human carbonic anhydrase IX can be used as active compounds of pharmaceuticals for diagnostics and/or therapy of cancer diseases.Type: GrantFiled: October 24, 2012Date of Patent: March 22, 2016Assignees: USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CESKE REPUBLIKY, V.V.I., USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY, V.V.I., USTAV ANORGANICKE CHEMIE AKADEMIE VED CESKE REPUBLIKY, V.V.I., UNIVERZITA PALACKEHO V OLOMOUCIInventors: Jiri Brynda, Petr Cigler, Bohumir Gruner, Pavlina Maloy Rezacova, Pavel Mader, Vaclav Sicha, Mario Bakardjiev, Josef Holub, Petr Dzubak, Marian Hajduch
-
Publication number: 20140336073Abstract: A method for determining the sensitivity and/or resistance of a patient suffering from a cancer disease to Aurora kinase inhibitor therapy, which comprises determining in vitro in the cancer cells or body fluids taken from the patient the expression of at least one gene selected from a particular group and/or determining in vitro in the cancer cells or body fluids taken from the patient the level of at least one protein selected from a particular group.Type: ApplicationFiled: December 7, 2012Publication date: November 13, 2014Applicants: PALACKY UNIVERSITY, OLOMOUC, INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS ASCR, V.V.I.Inventors: Madhusudhan Reddy Kollaredy, Marian Hajduch, Petr Dzubak, Josef Srovnal, Rita Hrabakova, Hana Kovarova
-
Publication number: 20140303390Abstract: Derivatives of boron cluster compounds of general formula I and their pharmaceutically acceptable salts and solvates, and their specific inhibition effect on the enzyme carbonic anhydrase IX, a protein overexpressed in cancer tissues. Methods of synthesis and the use of the novel derivatives. These inhibitors of human carbonic anhydrase IX can be used as active compounds of pharmaceuticals for diagnostics and/or therapy of cancer diseases.Type: ApplicationFiled: October 24, 2012Publication date: October 9, 2014Applicants: UNIVERZITA PALACKEHO V OLOMOUCI, USTAV ORGANICKE CHEMIE A BIOCHEME AKADEMIE VED CESKE REPUBLIKY, v.v.i., USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY, v.v.iInventors: Jiri Brynda, Petr Cigler, Bohumir Gruner, Pavlina Maloy Rezacova, Pavel Mader, Vaclav Sicha, Mario Bakardjiev, Josef Holub, Petr Dzubak, Marian Hajduch